Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.62 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.49 |
| ▸ | WNT3A | P56704 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22027767 | 0.87 | CTNNB1 (0.55) | PRKCITAS1R3TAS1R1RAB9ANPC1 | |
| SCHEMBL20330490 | 0.87 | CTNNB1 (0.55) | PRKCITAS1R3TAS1R1RAB9ANPC1 | |
| SCHEMBL19932401 | 0.86 | TSHR (0.47) | PRKCITAS1R3TAS1R1RAB9ANPC1 | |
| SCHEMBL11022359 | 0.85 | PRKCI (0.66) | PRKCITAS1R3TAS1R1RAB9ANPC1 | |
| SCHEMBL1395976 | 0.84 | PRKCI (0.64) | PRKCITAS1R3TAS1R1RAB9ANPC1 | |
| SCHEMBL29503137 | 0.84 | PRKCI (0.69) | PRKCITAS1R3TAS1R1RAB9ANPC1 | |
| SCHEMBL2176489 | 0.84 | PRKCI (0.69) | PRKCITAS1R3TAS1R1RAB9ANPC1 | |
| SCHEMBL27392330 | 0.83 | PRKCI (0.42) | PRKCITAS1R3TAS1R1RAB9ANPC1 | |
| SCHEMBL23222198 | 0.82 | PRKCI (0.62) | PRKCITAS1R3TAS1R1RAB9ANPC1 | |
| SCHEMBL102518 | 0.82 | PRKCI (0.62) | PRKCITAS1R3TAS1R1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024153244-A1 | NITROGEN-CONTAINING COMPOUND | 南京再明医药有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-107743483-B | NADPH oxidase 4 inhibitors | 埃科特莱茵药品有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELTION PHARMACEUTICALS LTD (CH) | 2021-12-23 | — | — | US | disclosed |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2021-10-05 | — | — | US | disclosed |
| EP-3310767-B1 | 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-07-22 | — | — | EP | disclosed |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-05-28 | — | — | US | disclosed |
| US-10584118-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2020-03-10 | — | — | US | disclosed |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | disclosed |
| EP-3310767-A1 | NADPH OXIDASE 4 INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2018-04-25 | — | — | EP | disclosed |
| EP-2594555-B1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA PHARM CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004032848-A2 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004026843-A1 | BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ARROW THERAPEUTICS LIMITED (GB) | 2004-04-01 | — | — | WO | disclosed |
| US-6245778-B1 | 1,6-naphthyridine anti-convulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-06-12 | — | — | US | disclosed |
| EP-0986559-A1 | 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998054184-A1 | 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1998-12-03 | — | — | WO | disclosed |
| WO-1995025099-A1 | 2-CYANO-1,3-DIONE DERIVATIVES USEFUL AS HERBICIDES | RHONE-POULENC AGRICULTURE LTD. (GB) | 1995-09-21 | — | — | WO | disclosed |
| US-4333759-A | Herbicidal 5-cyano-2,3-dihydro-benzofuran-2-ones | FISONS LIMITED (GB) | 1982-06-08 | — | — | US | disclosed |
| US-4263037-A | 5-Cyano-2,3-dihydrobenzofurans useful as herbicides | FISONS LIMITED (GB) | 1981-04-21 | — | — | US | disclosed |
| EP-0007719-A2 | Cyanbenzofuran derivatives, processes for their preparation and their use in herbicidal compositions; cyanobenzene, benzodioxepine, benzodioxaphosphepine and benzodioxathiepine derivatives | FBC LIMITED (GB) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10584118-B2 | NADPH oxidase 4 inhibitors | NOX4, NOX1, CYBB | PRKCI 2510/4885TAS1R3 4499/4885TAS1R1 4252/4885 |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | PRKCI 2510/4885TAS1R3 4499/4885TAS1R1 4252/4885 |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, PTGDR, LTB4R2 | PRKCI 3389/4885TAS1R3 1979/4885TAS1R1 1358/4885 |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | NOX4, NOX1, CYBB | PRKCI 2510/4885TAS1R3 4499/4885TAS1R1 4252/4885 |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | PRKCI 2510/4885TAS1R3 4499/4885TAS1R1 4252/4885 |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | PRKCI 2510/4885TAS1R3 4499/4885TAS1R1 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.